Form 4: Ionis Pharmaceuticals Director Michael J. Yang Acquires Shares Through Vesting of Restricted Stock Units

Director Michael J. Yang of Ionis Pharmaceuticals acquired 1,931 shares of common stock through the vesting of restricted stock units.

Summary

• Michael J. Yang, a director at Ionis Pharmaceuticals, acquired 1,931 shares of common stock on January 15, 2025.
• The acquisition resulted from the vesting of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of Ionis common stock or its equivalent cash value.
• The RSUs vest in three equal annual installments.
• Following the transaction, Mr. Yang directly owns 7,939 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed positively as it aligns the interests of management with shareholders. There is no indication of any negative sentiment.

Positives

• The vesting of restricted stock units indicates a positive incentive structure for company directors.
• The acquisition of shares by a director can be seen as a sign of confidence in the company's future performance.

Industry Context

This is a standard transaction for a company that uses stock-based compensation as part of its executive compensation plan. It is common for directors to receive restricted stock units that vest over time.

Comparison to Industry Standards

• Stock-based compensation, including restricted stock units, is a common practice among publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen also use RSUs as part of their compensation packages for executives and directors.
• The vesting schedule of three equal annual installments is also a typical vesting structure.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the interests of the director with the company's performance.
• The vesting of RSUs is a standard part of the compensation package for directors and is not expected to have a significant impact on other stakeholders.

Key Dates

Keywords

Ionis Pharmaceuticals, Michael J. Yang, Restricted Stock Units, Share Acquisition, Director, Vesting, Common Stock